X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9%
Fri, 27 Jul

DR. REDDYS LAB has announced its results for the quarter ended June 2018. Here is a detailed performance review of the same:

DR. REDDYS LAB Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-17*
3
Mar-18*
3
Jun-18*
QoQ ChangeYoY Change
Net SalesRs m33,33235,53937,3655.1%12.1%
Other incomeRs m38044950412.2%32.6%
TurnoverRs m33,71235,98837,8695.2%12.3%
ExpensesRs m30,10029,90329,677-0.8%-1.4%
Gross profitRs m3,3305,7057,77136.2%133.4%
DepreciationRs m2,5922,7632,7870.9%7.5%
InterestRs m2151781959.6%-9.3%
Profit before taxRs m9033,2135,29364.7%486.2%
TaxRs m2374925328.1%124.5%
Profit after taxRs m6662,7214,76175.0%614.9%
Gross profit margin%10.016.120.8
Effective tax rate%26.215.310.1
Net profit margin%2.07.612.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 12.1% on a year-on-year (YoY) basis. The expenses were down by 1.4% YoY during the same period.
  • The company's operating profit increased by 133.4% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.8% in 1QFY19 as against 10.0% in 1QFY18.
  • Depreciation charges and finance costs increased by 7.5% YoY and 9.3% YoY, respectively.
  • Other income increased by 32.6% YoY during the quarter.
  • Net profit for the quarter increased by 614.9% YoY. Net profit margins during the quarter increased from 2.0% in 1QFY18 to 12.6% in 1QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 5.1% on a quarter-on-quarter (QoQ) basis. The expenses were down by 0.8% QoQ during the same period.
  • The company's operating profit increased by 36.2% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.8% in 1QFY19 as against 16.1% in 4QFY18.
  • Net profit for the quarter increased by 75.0% QoQ, while net profit margins increased from 7.6% in 4QFY18 to 12.6% in 1QFY19.

To see how DR. REDDYS LAB has performed over the last eight quarters, please visit here.

DR. REDDYS LAB Share Price Performance

Over the last one year, DR. REDDYS LAB share price has moved up from Rs 2,621.5 to Rs 2,085.1, registering a Loss of Rs 536.4 or around 20.5%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,056.0 (up 0.7%). Over the last one year it has moved down from 14,668.6 to 14,056.0, a gain of 613 points (down 4.2%).

Overall, the S&P BSE SENSEX is up 0.8% over the year.

Current Valuations

At the current price of Rs 2,085.1, the price to earnings (P/E) ratio of DR. REDDYS LAB stands at 25.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.7 times.

Equitymaster requests your view! Post a comment on "DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9%". Click here!

  

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 15, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - SANOFI INDIA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS